OpenSSL SSL_connect: Connection reset by peer in connection to v2.sherpa.ac.uk:443 PuSH - Publication Server of Helmholtz Zentrum München: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

PuSH - Publication Server of Helmholtz Zentrum München

Debiec-Rychter, M.* ; Sciot, R.* ; Le Cesne, A.* ; Schlemmer, M. ; Hohenberger, P.* ; van Oosterom, A.T.* ; Blay, J.Y.* ; Leyvraz, S.* ; Stul, M.* ; Casali, P.G.* ; Zalcberg, J.* ; Verweij, J.* ; van Glabbeke, M.* ; Hagemeijer, A.* ; Judson, I.* ; EORTC Soft Tissue and Bone Sarcoma Group (*) ; Italian Sarcoma Group (*)

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Eur. J. Cancer 42, 1093-1103 (2006)
PMC
Open Access Green as soon as Postprint is submitted to ZB.
A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival. The current analysis of that study aimed to assess if tumour mutational status correlates with clinical response to imatinib. Pre-treatment samples of GISTs from 377 patients enrolled in phase III study were analyzed for mutations of KIT or PDGFRA by combination of D-HPLC and direct sequencing of tumour genomic DNA. Mutation types were correlated with patients' survival data. The presence of exon 9-activating mutations in KIT was the strongest adverse prognostic factor for response to imatinib, increasing the relative risk of progression by 171% (P<0.0001) and the relative risk of death by 190% (P<0.0001) when compared with KIT exon 11 mutants. Similarly, the relative risk of progression was increased by 108% (P<0.0001) and the relative risk of death by 76% (P=0.028) in patients without detectable KIT or PDGFRA mutations. In patients whose tumours expressed an exon 9 KIT oncoprotein, treatment with the high-dose regimen resulted in a significantly superior progression-free survival (P=0.0013), with a reduction of the relative risk of 61%. We conclude that tumour genotype is of major prognostic significance for progression-free survival and overall survival in patients treated with imatinib for advanced GISTs. Our findings suggest the need for differential treatment of patients with GISTs, with KIT exon 9 mutant patients benefiting the most from the 800 mg daily dose of the drug.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords gastrointestinal stromal tumours; KIT; imatinib mesylate; genotype analysis
ISSN (print) / ISBN 0959-8049
e-ISSN 1879-0852
Journal European Journal of Cancer
Quellenangaben Volume: 42, Issue: 8, Pages: 1093-1103 Article Number: , Supplement: ,
Publisher Elsevier
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) CCG Tumor Therapy with Hyperthermia (IMI-KTH)